These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18708372)

  • 21. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4 years after withdrawal of rofecoxib: where do we stand today?
    Jaksch W; Dejaco C; Schirmer M
    Rheumatol Int; 2008 Oct; 28(12):1187-95. PubMed ID: 18663451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analgesics, NSAIDS, and coxibs in rheumatic pain].
    Di Matteo L
    Reumatismo; 2006; 58 Spec No.1():84-9. PubMed ID: 23631071
    [No Abstract]   [Full Text] [Related]  

  • 26. How to advise aspirin use in patients who need NSAIDs.
    Sopena F; Lanas A
    Curr Pharm Des; 2007; 13(22):2248-60. PubMed ID: 17691998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
    Arber N
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
    Huls G; Koornstra JJ; Kleibeuker JH
    Lancet; 2003 Jul; 362(9379):230-2. PubMed ID: 12885487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoprevention of colorectal cancer: Past, present, and future.
    Umezawa S; Higurashi T; Komiya Y; Arimoto J; Horita N; Kaneko T; Iwasaki M; Nakagama H; Nakajima A
    Cancer Sci; 2019 Oct; 110(10):3018-3026. PubMed ID: 31361372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoprevention with special reference to inherited colorectal cancer.
    Lynch PM
    Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
    Kimmey MB
    Am J Med; 2004 Sep; 117 Suppl 5A():72S-78S. PubMed ID: 15478856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of NSAIDs for the chemoprevention of colorectal cancer.
    Herendeen JM; Lindley C
    Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
    Patrono C; Baigent C
    Mol Interv; 2009 Feb; 9(1):31-9. PubMed ID: 19299662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
    Rostom A; Dubé C; Lewin G; Tsertsvadze A; Barrowman N; Code C; Sampson M; Moher D;
    Ann Intern Med; 2007 Mar; 146(5):376-89. PubMed ID: 17339623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.